Abstract
Background Evidence exists that even at high CD4 counts, mortality among HIV-infected antiretroviral therapy (ART) naïve individuals is higher than that in the general population. However, many developing countries still initiate ART at CD4 ≤350 cells/mm3. Objective To compare mortality among HIV-infected ART naïve individuals with CD4 counts ≥350 cells/mm3 with mortality in the general Ugandan population and to investigate risk factors for death. Design Population-based prospective HIV cohort. Methods The study population consisted of HIV-infected people in rural southwest Uganda. Patients were reviewed at the study clinic every 3 months. CD4 cell count was measured every 6 months. Rate ratios were estimated using Poisson regression. Indirect methods were used to calculate standardised mortality ratios (SMRs). Results A total of 374 participants with CD4 ≥350 cells/mm3 were followed for 1,328 person-years (PY) over which 27 deaths occurred. Mortality rates (MRs) (per 1,000 PY) were 20.34 (95% CI: 13.95–29.66) among all participants and 16.43 (10.48–25.75) among participants aged 15–49 years. Mortality was higher in periods during which participants had CD4 350–499 cells/mm3 than during periods of CD4 ≥500 cells/mm3 although the difference was not statistically significant [adjusted rate ratio (aRR)=1.52; 95% CI: 0.71–3.25]. Compared to the general Ugandan population aged 15–49 years, MRs were 123% higher among participants with CD4 ≥500 cells/mm3 (SMR: 223%, 95% CI: 127–393%) and 146% higher among participants with CD4 350–499 cells/mm3 (246%, 117%–516). After adjusting for current age, mortality was associated with increasing WHO clinical stage (aRR comparing stage 3 or 4 and stage 1: 10.18, 95% CI: 3.82–27.15) and decreasing body mass index (BMI) (aRR comparing categories ≤17.4 Kg/m2 and ≥18.5 Kg/m2: 6.11, 2.30–16.20). Conclusion HIV-infected ART naïve individuals with CD4 count ≥350 cells/mm3 had a higher mortality than the general population. After adjusting for age, the main predictors of mortality were WHO clinical stage and BMI.
Highlights
Evidence exists that even at high CD4 counts, mortality among HIV-infected antiretroviral therapy (ART) naıve individuals is higher than that in the general population
Mortality was higher in periods during which participants had CD4 350Á499 cells/mm3 than during periods of CD4 ]500 cells/mm3 the difference was not statistically significant [adjusted rate ratio01.52; 95% CI: 0.71Á3.25]
After adjusting for current age, mortality was associated with increasing World Health Organization (WHO) clinical stage and decreasing body mass index (BMI)
Summary
Evidence exists that even at high CD4 counts, mortality among HIV-infected antiretroviral therapy (ART) naıve individuals is higher than that in the general population. Objective: To compare mortality among HIV-infected ART naıve individuals with CD4 counts ]350 cells/ mm with mortality in the general Ugandan population and to investigate risk factors for death. Mortality was higher in periods during which participants had CD4 350Á499 cells/mm than during periods of CD4 ]500 cells/mm the difference was not statistically significant [adjusted rate ratio (aRR)01.52; 95% CI: 0.71Á3.25]. Compared to the general Ugandan population aged 15Á49 years, MRs were 123% higher among participants with CD4 ]500 cells/mm (SMR: 223%, 95% CI: 127Á393%) and 146% higher among participants with CD4 350Á499 cells/mm (246%, 117%Á516). Conclusion: HIV-infected ART naıve individuals with CD4 count ]350 cells/mm had a higher mortality than the general population. After adjusting for age, the main predictors of mortality were WHO clinical stage and BMI
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.